Glaucoma QOL questionnaire ticks the right boxes

Article

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension.

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension (OHT), according to the results of a study published online ahead of print by Acta Ophthalmologica Scandinavica.

Alain Béchetoille from Paris and colleagues from across France enrolled patients with OHT or glaucoma (n=573) to take part in a cross-sectional psychometric validation study and a separate reproducibility study (n=244). Each subject answered the 36-item Glau-Qol questionnaire, which was designed from in-depth patient interviews.

The clinical validity of the questionnaire was found to be excellent. It clearly demonstrated that as disease severity and visual field impairment increased, health-related quality of life (HRQoL) scores from psychological wellbeing, self-image, daily life, driving, anxiety and burden of treatment domains were negatively affected. Increased age and lower visual acuity were also associated with lower HRQoL scores but to a lesser extent.

Psychometric validation demonstrated acceptable convergent and discriminant validity of the Glau-QoL and good reproducibility, with intra-class correlation coefficients and concordance correlation coefficients ≥0.69.

It was the conclusion of the researchers that the Glau-QoL questionnaire is a valid instrument that demonstrates excellent correlations with disease progression in patients with glaucoma and OHT.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.